Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490274 | 0.84 | STING1 (0.59) | GAASTING1ALDH1A1KDM4EATM | |
| SCHEMBL15641724 | 0.83 | MAPT (0.49) | MAPK1CYP1A2CYP3A4GAAMAPT | |
| SCHEMBL4506896 | 0.82 | STING1 (0.50) | MAPK1GAAMAPTSTING1ATM | |
| SCHEMBL28274741 | 0.82 | STING1 (0.50) | MAPK1GAAMAPTSTING1ATM | |
| SCHEMBL14889338 | 0.79 | STING1 (0.55) | GAAMAPTSTING1ALDH1A1MEN1 | |
| SCHEMBL28736881 | 0.78 | STING1 (0.74) | STING1ALDH1A1ATM | |
| SCHEMBL3234925 | 0.77 | MAPK1 (1.00) | MAPK1CYP1A2CYP3A4GAAMAPT | |
| SCHEMBL384965 | 0.76 | STING1 (0.63) | STING1MEN1KMT2A | |
| SCHEMBL22234314 | 0.76 | STING1 (0.48) | GAAMAPTSTING1ALDH1A1ATM | |
| SCHEMBL1596152 | 0.75 | STING1 (0.61) | CYP1A2STING1MEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| CN-101605758-A | Methods of treating hepatitis C | PTC THERAPEUTICS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1984332-A2 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | MAPK1 4248/4885CYP1A2 3179/4885CYP3A4 3086/4885 |
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | MAPK1 4/4885CYP1A2 1743/4885CYP3A4 2235/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | MAPK1 4248/4885CYP1A2 3179/4885CYP3A4 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.